Why Europe’s CDMO Sector Must Learn to Dance with Disruption
For CDMOs, the storms of de-industrialization, Brexit, and the Biosecure Act are not existential threats but the very winds that can propel them forward.
False
For CDMOs, the storms of de-industrialization, Brexit, and the Biosecure Act are not existential threats but the very winds that can propel them forward.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
November 13, 2026
1 min read
Fujifilm Cellular Dynamics’ Delara Motlagh discusses her path into cell and gene therapy, the challenges of scaling manufacturing, and the potential of iPSC technologies
November 12, 2026
5 min read
How next-generation biomarker strategies could improve patient stratification, strengthen clinical trials, and reduce the cost of drug development
November 11, 2026
2 min read
The deal adds viral vector, bioconjugation, payload-linker, and advanced drug-delivery capabilities to Lonza’s manufacturing network
November 2, 2026
5 min read
Early characterization and manufacturing planning can help developers choose the right formulation strategy for complex oral therapies
False
Affiliations:
Specialties:
Areas of Expertise: